Skip to content
S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics episode artwork

Jul 10, 2025 25 min

S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

from National Pharmaceutical Congress (NPC) Podcast Hosted by Jeremy Visser

Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator’s Award, and earlier detection for ALS. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

0:00 25:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of National Pharmaceutical Congress (NPC) Podcast?

This episode is 25 minutes long.

When was this National Pharmaceutical Congress (NPC) Podcast episode published?

This episode was published on July 10, 2025.

Can I download this National Pharmaceutical Congress (NPC) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.